210 related articles for article (PubMed ID: 33299660)
1. Co-localization of CD169
Björk Gunnarsdottir F; Auoja N; Bendahl PO; Rydén L; Fernö M; Leandersson K
Oncoimmunology; 2020 Nov; 9(1):1848067. PubMed ID: 33299660
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer.
Shiota T; Miyasato Y; Ohnishi K; Yamamoto-Ibusuki M; Yamamoto Y; Iwase H; Takeya M; Komohara Y
PLoS One; 2016; 11(11):e0166680. PubMed ID: 27861544
[TBL] [Abstract][Full Text] [Related]
3. CD169
Tacconi C; Commerford CD; Dieterich LC; Schwager S; He Y; Ikenberg K; Friebel E; Becher B; Tugues S; Detmar M
Cell Rep; 2021 Apr; 35(2):108993. PubMed ID: 33852863
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma.
Ohnishi K; Yamaguchi M; Erdenebaatar C; Saito F; Tashiro H; Katabuchi H; Takeya M; Komohara Y
Cancer Sci; 2016 Jun; 107(6):846-52. PubMed ID: 26991548
[TBL] [Abstract][Full Text] [Related]
5. Loss of CD169
Topf MC; Harshyne L; Tuluc M; Mardekian S; Vimawala S; Cognetti DM; Curry JM; Rodeck U; Luginbuhl A
Otolaryngol Head Neck Surg; 2019 Jul; 161(1):67-73. PubMed ID: 30744470
[TBL] [Abstract][Full Text] [Related]
6. CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis.
Asano T; Ohnishi K; Shiota T; Motoshima T; Sugiyama Y; Yatsuda J; Kamba T; Ishizaka K; Komohara Y
Cancer Sci; 2018 May; 109(5):1723-1730. PubMed ID: 29520898
[TBL] [Abstract][Full Text] [Related]
7. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma.
Ohnishi K; Komohara Y; Saito Y; Miyamoto Y; Watanabe M; Baba H; Takeya M
Cancer Sci; 2013 Sep; 104(9):1237-44. PubMed ID: 23734742
[TBL] [Abstract][Full Text] [Related]
8. Reduced number of CD169
Strömvall K; Sundkvist K; Ljungberg B; Halin Bergström S; Bergh A
Prostate; 2017 Nov; 77(15):1468-1477. PubMed ID: 28880401
[TBL] [Abstract][Full Text] [Related]
9. Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses.
Komohara Y; Ohnishi K; Takeya M
Cancer Sci; 2017 Mar; 108(3):290-295. PubMed ID: 28002629
[TBL] [Abstract][Full Text] [Related]
10. High CD169 expression in lymph node macrophages predicts a favorable clinical course in patients with esophageal cancer.
Takeya H; Shiota T; Yagi T; Ohnishi K; Baba Y; Miyasato Y; Kiyozumi Y; Yoshida N; Takeya M; Baba H; Komohara Y
Pathol Int; 2018 Dec; 68(12):685-693. PubMed ID: 30516869
[TBL] [Abstract][Full Text] [Related]
11. Natural compounds that regulate lymph node sinus macrophages: Inducing an anti-tumor effect by regulating macrophage activation.
Fujiwara Y; Saito Y; Shiota T; Cheng P; Ikeda T; Ohnishi K; Takeya M; Komohara Y
J Clin Exp Hematop; 2018; 58(1):17-23. PubMed ID: 29553092
[TBL] [Abstract][Full Text] [Related]
12. CD169
Briem O; Källberg E; Kimbung S; Veerla S; Stenström J; Hatschek T; Hagerling C; Hedenfalk I; Leandersson K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831605
[TBL] [Abstract][Full Text] [Related]
13. Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration.
Kawaguchi S; Kawahara K; Fujiwara Y; Ohnishi K; Pan C; Yano H; Hirosue A; Nagata M; Hirayama M; Sakata J; Nakashima H; Arita H; Yamana K; Gohara S; Nagao Y; Maeshiro M; Iwamoto A; Hirayama M; Yoshida R; Komohara Y; Nakayama H
Cancer Immunol Immunother; 2022 Sep; 71(9):2127-2139. PubMed ID: 35044489
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma.
Saito Y; Ohnishi K; Miyashita A; Nakahara S; Fujiwara Y; Horlad H; Motoshima T; Fukushima S; Jinnin M; Ihn H; Takeya M; Komohara Y
Cancer Immunol Res; 2015 Dec; 3(12):1356-63. PubMed ID: 26297710
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer associated CD169
Gunnarsdottir FB; Briem O; Lindgren AY; Källberg E; Andersen C; Grenthe R; Rosenqvist C; Millrud CR; Wallgren M; Viklund H; Bexell D; Johansson ME; Hedenfalk I; Hagerling C; Leandersson K
Front Immunol; 2023; 14():1180209. PubMed ID: 37404831
[TBL] [Abstract][Full Text] [Related]
16. Melanoma growth and lymph node metastasis is independent of host CD169 expression.
Muhsin-Sharafaldine MR; Saunderson SC; Dunn AC; McLellan AD
Biochem Biophys Res Commun; 2017 May; 486(4):965-970. PubMed ID: 28359758
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
Front Immunol; 2018; 9():1997. PubMed ID: 30237798
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of CD169-positive macrophages in various tumors: a meta-analysis.
Kong W; Wei M; Liu R; Zhang J; Wang X
Bioengineered; 2021 Dec; 12(1):8505-8514. PubMed ID: 34607536
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer cells promote CD169
Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
[TBL] [Abstract][Full Text] [Related]
20. CD169 mediates the capture of exosomes in spleen and lymph node.
Saunderson SC; Dunn AC; Crocker PR; McLellan AD
Blood; 2014 Jan; 123(2):208-16. PubMed ID: 24255917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]